Table 2.
Patients' treatment, HR, and outcomes
| Days to | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient (gender‐age) | Therapy (+RDV) | HR before RDV median (IQR) | HR during RDV median (IQR) | p a | HR after RDV median (IQR) | p b | Apyrexia | Stop O2 therapy | Dischargec | Outcome |
| Pt 1 (M‐74) | DXM, HP, LMWH | 60 (60–61) | 52.5 (50–55) | .049 | 60 (54.5–70.75) | .025 | 1 | 7 | 7 (14) | Pos |
| Pt 2 (M‐69) | DXM, LMWH | 81 (79–85) | 68 (64.5–70.5) | <.01 | 70 (65–73) | >.1 | 1 | 18 | 19 (27) | Pos |
| Pt 3 (M‐65) | DXM, LMWH | 60.5 (58–64.5) | 55 (55–62) | >.1 | 69 (65.75–70.75) | <.01 | 0 | 9 | 10 (13) | Pos |
| Pt 4 (M‐54) | DXM, LMWH | 63 (56.75–65.5) | 67 (56.5–72) | >.1 | 69.5 (62.5–70.75) | >.1 | 1 | 13 | 13 (17) | Pos |
| Pt 5 (M‐47) | DXM, HP, LMWHd | 81.5 (67.25–84) | 62.5 (49.5–70.25) | .011 | 65 (59.5–68.5) | >.1 | 7 | 25d | 16 (25) | Pos |
| Pt 6 (M‐82) | DXM, LMWHd | 80.5 (78.5–81.75) | 71 (59.5–75) | <.01 | 73 (62.75–81.75) | >.1 | 1 | 13d | 13 (13) | Pos |
| Pt 7 (F‐59) | DXM, LMWH | 65 (64–72) | 59.5 (56–62.75) | <.01 | 69 (64.25–72) | .055 | 4 | 15 | 13 (17) | Pos |
| Pt 8 (M‐88) | DXM, LMWH | 85 (81–88) | 65 (59–67) | <.01 | 69.5 (63.25–73.75) | >.1 | 3 | 11 | 5 (24) | Pos |
| Pt 9 (M‐69) | DXM, LMWHd | 65 (63–71.5) | 50 (48–57) | .026 | 79 (75–84) | <.01 | 7 | 43d | 33 (43) | Pos |
| Pt 10 (M‐69) | DXM, LMWH | 77 (75.5–77) | 65 (56.5–68) | .016 | 63 (58–66.5) | >.1 | 1 | 16 | 16 (16) | Pos |
| Pt 11 (M‐59) | DXM, LMWH | 55 (54–63) | 56 (52–60.5) | >.1 | 54 (53–57) | >.1 | 2 | 14 | 12 (15) | Pos |
| Pt 12 (F‐74) | DXM, LMWH | 55 (55–65) | 63 (55–65.5) | >.1 | 60 (58–66.5) | >.1 | 1 | 25 | 17 (28) | Pos |
| Pt 13 (F‐55) | DXM, HP, LMWH | 68.5 (63.25–73.75) | 64 (62–69) | >.1 | 80 (79–88) | <.01 | 2 | 14 | 8 (16) | Pos |
| Pt 14 (F‐64) | DXM, LMWH | 74 (71.5–77.25) | 71 (64.5–73.5) | >.1 | 68 (65.5–84.75) | >.1 | 0 | 9 | 6 (16) | Pos |
| Pt 15 (M‐46) | DXM, LMWH | 85 (78–89) | 73 (68.5–78) | .008 | 76.5 (74.25–79.5) | >.1 | 1 | 8 | 4 (10) | Pos |
| Pt 16 (F‐69) | DXM, HP, LMWH | 73 (66.75–77.75) | 65 (61.25–73) | >.1 | 72 (70–78) | >.1 | 1 | 10 | 9 (15) | Pos |
| Pt 17 (F‐67) | DXM, LMWH | 73 (71–74) | 60 (57–65) | .005 | 60 (59–63) | >.1 | 0 | 12 | 10 (12) | Pos |
| Pt 18 (M‐80) | DXM, LMWH | 66.5 (63.75–71) | 60 (57.75–62.5) | .012 | 48 (46.5–55) | .012 | 1 | NA | 17 (17) | Pos |
| Pt 19 (M‐63) | DXM, LMWHd | 74.5 (69.75–79.25) | 80 (72–81.75) | >.1 | 71 (66–75) | >.1 | 2 | NAd | 19 (19) | Pos |
| Pt 20 (F‐34) | DXM, LMWH | 88 (76–92) | 76 (70.5–82.5) | .03 | 85 (79.75–90.75) | .087 | 1 | 11 | 10 (12) | Pos |
Note: Bold values indicate statistically significant values.
Abbreviations: CCI, Charlson Comorbidity Index; DEX, dexamethasone; F, female; HR, heart rate; LMWH, low‐molecular‐weight heparin; M, male; NA, not available (patients were discharged with the indication to continue O2 therapy at home); neg, negative; pos, positive; Pt, patient; RDV, remdesivir.
Difference between median HR before RDV administration and median HR during RDV administration.
Difference between median HR during RDV administration and median HR after RDV administration.
Length of hospital stay and between brackets, length of hospital + intermediate/low‐care facility stay.
Patients treated with continuous positive airway pressure (CPAP).